RxDoctor Payments Data

Deepak Agarwal

Pain Medicine · Santa Barbara, CANPI 1417342981

Payments from drug & device makers

$13,139in general payments, 2019–2025

Across 87 payments — averaging $151.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$11K
  • Abbott$721
  • Nevro Corp.$583
  • Medtronic$577
  • Relievant Medsystems, Inc.$132
  • Amgen$113
  • plus $456 from 9 others
$16in research payments, 2019–2025

Across 1 payment — averaging $16.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Saluda Medical Americas, Inc.$16

What the payments were for

  • Consulting fees$1001%
  • Grants$10,07577%
  • Food & beverage$2,96423%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific13$10,557
Abbott30$721
Nevro Corp.15$583
Medtronic(2 entities)12$577
Relievant Medsystems, Inc.2$132
Amgen1$113
AbbVie5$111
Comsort, Inc1$100
Bioventus LLC1$91
Vertos Medical, Inc.2$53
Johnson & Johnson1$25
Merck1$24
Stryker1$22
Mindray DS USA, Inc.1$15
Bayer1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,139 in reported general payments places this provider in the 80th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$79,265
Medicare patients
221
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin12$130

Paid to pharmacies, not to this prescriber.

Other pain medicine in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →